Publications by authors named "Deian T Jelev"

Article Synopsis
  • Chronic obstructive pulmonary disease (COPD) is a manageable disease with various health impacts beyond the lungs, while hepatitis C virus (HCV) infection also has multiple non-liver-related health issues.
  • There is a notable overlap between the two conditions, as patients with COPD have higher rates of HCV, and those infected with HCV, particularly older individuals, tend to experience quicker deterioration of their lung function.
  • The article reviews research on the coexistence of COPD and HCV, examining their prevalence, underlying mechanisms, and the health consequences of having both conditions simultaneously.
View Article and Find Full Text PDF

The treatment with lamivudine leads to drug resistant mutations in 19 to 70% cases after 1- and 5-year therapy, respectively, associated with the risk of severe rebound of liver disease with alaninaminotransferase flare. In this situation, adefovir should be added, but this drug is not available in every country. We report three cases where we avoided the expected hepatic flare-ups by using IFN and isoprinosine.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Deian T Jelev"

  • - Deian T Jelev's research primarily focuses on the interrelationship between chronic obstructive pulmonary disease (COPD) and hepatitis C virus (HCV) infections, highlighting how these conditions can exacerbate each other's progression and manifestations in patients.
  • - His studies reveal that COPD patients have a significantly higher prevalence of HCV, which correlates with accelerated disease progression, particularly in older individuals with HCV infection.
  • - In another aspect of his work, Jelev has addressed the challenge of preventing hepatic flare-ups in hepatitis B e antigen (HBe) negative patients following lamivudine treatment discontinuation, demonstrating successful management strategies through the use of interferon and isoprinosine in select cases.